MRNA is trading at $76.20 (+5.11%) as buyers extend the recent post-earnings rally. A recent analysis says the move is tied to Moderna’s first-quarter update, stronger international vaccine deliveries, reiterated 2026 growth guidance, and multiple late-stage pipeline milestones.
The stock is also near 52-week highs, with sentiment helped by fresh analyst price-target bumps and continued optimism around its mRNA pipeline. Broader U.S. market strength is modest, so the move appears mainly company-specific.